Miltiadis Sougioultzoglou, CEOPromiCell is advancing STEAP1-based CAR-T therapies for solid tumors in collaboration with Fred Hutchinson Cancer Center (FHCC), positioning its lead programs around a target it believes can open a meaningful new chapter in cell therapy beyond liquid tumors.
Its scientific strategy centers on STEAP1-directed CAR-T constructs developed with its research partners. FHCC and Memorial Sloan Kettering Cancer Center were previously involved in the founding of Juno Therapeutics, which contributed to the development of the CAR-T therapy Breyanzi. This work established a proven track record in bringing cell therapies to the clinic.
“We envision becoming a premier cell therapy company for solid tumors, advancing innovative technologies while minimizing risk and bringing promising treatments to patients efficiently,” says Miltiadis Sougioultzoglou, CEO.
Developing Next-Generation CAR-T Therapies
How do next-generation CAR-T constructs address persistence, potency, and tumor escape challenges?
PromiCell’s next-generation constructs are designed to enhance persistence and potency while addressing tumor escape, immune evasion and disease relapse that can limit the long-term effectiveness of existing therapies.
At the center of its platform is STEAP1, a cell surface protein widely expressed in prostate cancer and several other epithelial malignancies. It views STEAP1 as a potentially enabling target for extending CAR-T therapy into solid tumors, where progress has historically been limited despite strong outcomes in hematologic malignancies. By engineering CAR-T cells that recognize this antigen, PromiCell aims to extend CAR-T therapy beyond hematological cancers.
Its lead program, PRO CAR-201A, is an autologous STEAP1-directed CAR-T therapy being evaluated in metastatic castration-resistant prostate cancer. The program, licensed from FHCC and currently open as a single-center phase 1 study that is supported by the National Cancer Institute’s Experimental Therapeutics Program (NExT), has successfully administered two dose levels. Interim data presented during the JPM Healthcare Conference in early 2026 showed early signals of on-target activity in solid tumors.
PromiCell is further advancing its platform through PRO CAR-202, an IL-18 armored CAR-T therapy designed to secrete IL-18 within the tumor microenvironment to strengthen immune activation and sustain CAR-T persistence in solid tumor settings that typically suppress immune activity.
Why is IL-18 armored CAR-T technology important for improving immune activation in tumors?
Building on this program, it is also developing PRO CAR-201B, which uses the same STEAP1 CAR-T construct for the treatment of Ewing sarcoma, a rare and aggressive cancer affecting children and young adults. Preclinical safety and efficacy studies have recently been completed, with plans to submit an IND application to the FDA.
-
We envision becoming a premier cell therapy company for solid tumors, advancing innovative technologies while minimizing risk and bringing promising treatments to patients efficiently.
PromiCell is further advancing its platform through PRO CAR-202, an IL-18 armored CAR-T therapy designed to secrete IL-18 within the tumor microenvironment to strengthen immune activation and sustain CAR-T persistence in solid tumor settings that typically suppress immune activity.
Beyond its lead STEAP1 programs, the company is expanding into additional immunotherapy approaches, including PRO TCR-401, an HA-1 TCR-T therapy for leukemia relapse following bone marrow transplantation, and PRO CAR-301, an IL-18 armored CD33-directed CAR-T therapy targeting acute myeloid eukemia.
Expanding a Multi-Program Pipeline for Clinical Growth
In what way does pipeline diversification support clinical growth across multiple cancer indications?
PromiCell’s development strategy extends beyond prostate cancer. Additional programs targeting Ewing sarcoma and pancreatic cancer are advancing toward clinical development. The pancreatic cancer program incorporates a different interleukin-containing construct originating from the laboratory of researcher John Lee.
Additional licensing efforts targeting lung and bladder cancers are also in place, broadening its solid tumor portfolio and bringing the number of clinical-stage technologies under development to four within a single year.
Through a pipeline of cell and gene therapy programs, PromiCell is advancing multiple clinical-stage assets while expanding into additional solid tumor indications. It combines academic collaboration, focused clinical development and advances in cell therapy manufacturing to strengthen its path toward patients with limited therapeutic alternatives.
PromiCell is preparing for a potential NASDAQ listing while continuing to generate clinical data and secure manufacturing and commercial partnerships to support program expansion and eventual commercialization.
Through continued clinical progression, institutional collaboration and manufacturing scale-up, PromiCell is positioning its STEAP1-based platform to advance into later-stage trials and potential commercialization in solid tumor oncology. It is also advancing manufacturing readiness through work with experienced cell therapy partners to enable rapid production, timely technology transfer and commercial scale-up as programs progress.
Advancing Cell Therapy Innovation for Solid Tumor Breakthroughs
Cell and gene therapy has moved from experimental promise to clinical reality in hematologic cancers, yet progress in solid tumors remains uneven. Many programs continue to demonstrate safety without translating into meaningful efficacy, leaving executives responsible for therapeutic strategy and pipeline expansion facing a familiar dilemma: abundant innovation, limited clinical differentiation. The congestion around liquid tumors has created a false sense of maturity. In contrast, the far larger opportunity in solid tumors demands a different level of biological targeting, construct design and translational discipline.
A clear pattern has emerged in programs that show early signs of traction. The most credible approaches begin with validated biological targets that demonstrate consistent expression across multiple tumor types, reducing uncertainty in both trial design and downstream scalability. Scientific novelty alone is insufficient; sustained expression, defensible intellectual property and translational relevance increasingly determine whether a platform can move beyond early-stage validation into repeatable clinical success. Programs that fail to anchor themselves in such targets often stall in proof-of-concept phases, unable to generate the depth of efficacy data required for later-stage advancement or broader clinical confidence among stakeholders.
Another dividing line lies in how therapies are engineered to function within the hostile microenvironment of solid tumors. Conventional constructs often lose persistence or potency once introduced into circulation, limiting their ability to sustain therapeutic impact. Emerging approaches attempt to address this by enhancing durability and functional activity within the tumor setting, not merely achieving initial response but maintaining it over time. This shift reflects a broader recognition that efficacy in solid tumors depends as much on biological endurance as on initial targeting precision and immune engagement within complex tumor biology.
Execution capability further distinguishes credible platforms from speculative ones. Institutions and development environments with deep experience in cell therapy trials play a critical role in anticipating complications, refining protocols and accelerating progression through clinical phases. Programs embedded within such ecosystems benefit from established clinical infrastructure, experienced investigators and a feedback loop between discovery and application that reduces trial inefficiencies. Manufacturing readiness also becomes a decisive factor, as therapies must transition from controlled clinical settings to scalable production without compromising consistency, cost efficiency or timelines required for broader patient access.
PromiCell aligns closely with these emerging expectations. It builds its platform around STEAP1, a target with strong expression across several solid tumor types, positioning its pipeline to address indications where current therapies have struggled to demonstrate efficacy. Its approach incorporates enhanced constructs designed to extend persistence and potency, reflecting a focus on sustained therapeutic activity rather than incremental improvements.Collaboration with leading cancer centers such as Fred Hutchinson Cancer Center and Memorial Sloan Kettering Cancer Center anchors its clinical development within institutions known for advancing cell therapy into practice. It is also preparing for rapid manufacturing pathways and commercial partnerships to support progression into later-stage trials and eventual market entry.Its expanding pipeline across prostate cancer, sarcoma and additional solid tumor indications reflects a deliberate effort to build breadth without diluting focus. Taken together, its strategy reflects a disciplined effort to move solid tumor cell therapy beyond safety benchmarks toward clinically meaningful outcomes.
...Read more
CAR-T and TCR Therapy Info
Q1
What led PromiCell to be recognized among top CAR-T and TCR therapy technology providers?
PromiCell Therapeutics has established itself in CAR-T and TCR Therapy Technology by focusing on overcoming key limitations in current cancer immunotherapies. Its platform is designed to address tumor escape, relapse and immune evasion—three major barriers to durable treatment outcomes. By engineering next-generation cell therapies that enhance persistence and anti-tumor activity, the company demonstrates a strong commitment to improving clinical effectiveness. This targeted innovation approach underpins its recognition in CAR-T and TCR Therapy Technology.
Q2
How does PromiCell differentiate its approach to CAR-T and TCR therapy technology?
A next-generation engineering strategy defines how PromiCell delivers CAR-T and TCR Therapy Technology. Its CAR-T programs incorporate advanced features such as cytokine “armoring,” including IL-18 secretion, which enhances immune activation within the tumor microenvironment. This allows the therapy to sustain activity even in immunosuppressive conditions commonly seen in solid tumors. By improving both potency and durability, the company sets its CAR-T and TCR Therapy Technology apart from earlier generations.
Q3
How does PromiCell support therapeutic development across different cancer types?
PromiCell’s CAR-T and TCR Therapy Technology is designed for versatility across both hematologic and solid tumors. Its pipeline includes programs targeting antigens such as STEAP1 for prostate cancer and CD33 for acute myeloid leukemia, demonstrating broad applicability. These therapies are engineered to function effectively even in low-antigen environments, expanding their potential use cases. This diversified development strategy strengthens the practical reach of its CAR-T and TCR Therapy Technology.
Q4
What value does PromiCell’s technology bring to cancer treatment outcomes?
Enhanced efficacy and durability define the value of PromiCell’s CAR-T and TCR Therapy Technology. Preclinical studies have shown strong tumor regression and high disease control rates, supported by improved immune cell persistence and tumor microenvironment modulation. By enabling deeper and longer-lasting responses, the company’s therapies aim to reduce relapse rates and improve patient outcomes. These advantages highlight the transformative potential of its CAR-T and TCR Therapy Technology.
Q5
What role do scientific expertise and innovation play in its platform?
Scientific expertise is central to PromiCell’s CAR-T and TCR Therapy Technology. Its team includes pioneers in cell therapy who combine immunology, genetic engineering and translational research to design advanced therapeutic constructs. The platform integrates novel targets, engineered receptors and immune-enhancing mechanisms to create therapies that are both precise and scalable. This deep integration of expertise and innovation ensures continued advancement in CAR-T and TCR Therapy Technology.
Q6
Why is PromiCell relevant to the future of cancer immunotherapy?
The shift toward more personalized and durable cancer treatments has increased demand for advanced cell therapies, and PromiCell addresses this through its CAR-T and TCR Therapy Technology. Its focus on expanding CAR-T into solid tumors and leveraging TCR-based approaches for broader antigen recognition aligns with emerging trends in precision oncology. By addressing current limitations and improving therapeutic reach, the company remains highly relevant to the future of cancer immunotherapy.
